EPIX Pharmaceuticals' PRX-00023 Therapeutics CNS program in Phase 2B/3 offered for auction sale

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Aug 26 2009

Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that the PRX-00023 Therapeutics Program in Phase 2b/3 will be part of the intellectual property offered for sale at the September 30, 2009 auction.

The PRX-00023 is a CNS Therapeutics Program in Phase 2b/3. It is a small molecule, oral 5HT1A Agonist for CNS disorders. It is well tolerated with superior side effect profile compared to other 5HT1A agonists, SSRIs, and SNRIs. It has an open IND, some drug inventory available.

The intellectual property, regulatory dossier and clinical inventory will be sold at auction on September 30, 2009.

Source:

http://www.epixpharma.com 

Posted in: Drug Trial News

Tags: , , , ,

Comments (0)

Suggested Reading

Georgetown study raises concerns over aspirin's role in breast cancer treatment
Study reveals inflammation's role in long COVID's lingering effects
Vaccines targeting chronic diseases show promise in combatting age-related conditions
Mapping the Microbiome: Dr. Abidemi Junaid on the Groundbreaking Vagina Chip
Common HIV drugs linked to reduced Alzheimer's disease risk
Innovative levodopa infusion pump trial shows promise for reducing Parkinson's symptoms
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients
Study highlights global fertility decline and its implications for the future

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Lancet Commission predicts sharp increase in global prostate cancer cases